Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.
Profitability
This table compares Chugai Pharmaceutical and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Chugai Pharmaceutical | 35.09% | 23.76% | 19.92% |
| IM Cannabis | -39.62% | N/A | -58.32% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Chugai Pharmaceutical and IM Cannabis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Chugai Pharmaceutical | 0 | 3 | 1 | 1 | 2.60 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Chugai Pharmaceutical | $8.41 billion | 8.03 | $2.91 billion | $0.92 | 22.30 |
| IM Cannabis | $39.17 million | 0.03 | -$8.10 million | ($60.66) | -0.02 |
Chugai Pharmaceutical has higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Chugai Pharmaceutical has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.
Summary
Chugai Pharmaceutical beats IM Cannabis on 11 of the 14 factors compared between the two stocks.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
